These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
23. Dopaminergic modulation of cognitive function-implications for L-DOPA treatment in Parkinson's disease. Cools R Neurosci Biobehav Rev; 2006; 30(1):1-23. PubMed ID: 15935475 [TBL] [Abstract][Full Text] [Related]
24. [Therapeutic effect of budipin in treating Parkinson's disease]. Zhonghua Shen Jing Jing Shen Ke Za Zhi; 1985 Aug; 18(4):197-8. PubMed ID: 4075906 [No Abstract] [Full Text] [Related]
25. The effects of levodopa on word intelligibility in Parkinson's disease. De Letter M; Santens P; Van Borsel J J Commun Disord; 2005; 38(3):187-96. PubMed ID: 15748723 [TBL] [Abstract][Full Text] [Related]
26. Punding prevalence in Parkinson's disease. Miyasaki JM; Al Hassan K; Lang AE; Voon V Mov Disord; 2007 Jun; 22(8):1179-81. PubMed ID: 17230464 [TBL] [Abstract][Full Text] [Related]
27. Combined treatment in Parkinson's disease. Wheatley D Practitioner; 1983 Mar; 227(1377):446-7. PubMed ID: 6889232 [No Abstract] [Full Text] [Related]
28. [Two cases of Parkinson's disease in which visual hallucinations disappeared after cataract surgery]. Matsui H; Udaka F; Oda M; Kubori T; Nishinaka K; Kameyama M No To Shinkei; 2004 Apr; 56(4):351-4. PubMed ID: 15237728 [TBL] [Abstract][Full Text] [Related]
32. [Preliminary clinical trial of tetrahydropapaveroline in Parkinson's disease]. Dordain G; Goujet MA; Simon P Therapie; 1974; 29(3):421-34. PubMed ID: 4612860 [No Abstract] [Full Text] [Related]
33. Abnormal excitability of premotor-motor connections in de novo Parkinson's disease. Buhmann C; Gorsler A; Bäumer T; Hidding U; Demiralay C; Hinkelmann K; Weiller C; Siebner HR; Münchau A Brain; 2004 Dec; 127(Pt 12):2732-46. PubMed ID: 15509619 [TBL] [Abstract][Full Text] [Related]
34. Drug therapy for Parkinson's disease. Hermanowicz N Semin Neurol; 2007 Apr; 27(2):97-105. PubMed ID: 17390254 [TBL] [Abstract][Full Text] [Related]
35. Parkinson's focus. Parkinson's is debilitating but new treatments are on the horizon. Hermanns M RN; 2008 Oct; 71(10):24-8; quiz 29. PubMed ID: 18942321 [No Abstract] [Full Text] [Related]
36. Effect of medication in Parkinson's disease: a wavelet analysis of EMG signals. Strambi SK; Rossi B; De Michele G; Sello S Med Eng Phys; 2004 May; 26(4):279-90. PubMed ID: 15121053 [TBL] [Abstract][Full Text] [Related]
37. It was not just a heatwave! Neuroleptic malignant-like syndrome in a patient with Parkinson's disease. Douglas A; Morris J Age Ageing; 2006 Nov; 35(6):640-1. PubMed ID: 16943262 [TBL] [Abstract][Full Text] [Related]
38. Patterns of initial pharmacotherapy for Parkinson's disease in the United States. Huse DM; Castelli-Haley J; Orsini LS; Lenhart G; Abdalla JA J Geriatr Psychiatry Neurol; 2006 Jun; 19(2):91-7. PubMed ID: 16690994 [TBL] [Abstract][Full Text] [Related]